Lisa Taylor-Swanson, PhD, on a pilot in which integrative group medical visits improved menopause symptoms, knowledge, and self-efficacy.
|Articles|August 11, 2015
Behind the scenes of Contemporary OB/GYN’s redesign
Contemporary OB/GYN just got easier to read and easier to navigate. Our Editor-in-Chief and our designer show you how your journal just got better.
Advertisement
Contemporary OB/GYN just got easier to read and easier to navigate. Our Editor-in-Chief and our designer show you how your journal just got better.
Advertisement
Related to this article
Peter Hsin, BS, discusses a meta-analysis linking perioperative ketamine to lower early postpartum depressive symptoms after cesarean delivery.
A recap of the top video interviews from Contemporary OB/GYN's coverage of The Menopause Society 2026 Annual Meeting in San Diego.
Susan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.
The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.
A recap of the top women's health headlines from October 2026, including FDA approval of pritelivir for refractory HSV, ACOG's new menopause guideline, and more.
Chrisandra Shufelt, MD, on using a cardiovascular risk score to guide hormone therapy candidacy at menopause.
The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Choosing Among Hormonal and Nonhormonal VMS Therapies in Menopause
2
FDA removes boxed warnings from 3 more menopausal hormone therapy products
3
Top headlines in women's health from October 2026
4
Top video interviews from The Menopause Society 2026 Annual Meeting
5